<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03821935</url>
  </required_header>
  <id_info>
    <org_study_id>M19-345</org_study_id>
    <secondary_id>2018-004303-40</secondary_id>
    <nct_id>NCT03821935</nct_id>
  </id_info>
  <brief_title>Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the recommended Phase 2 dose (RP2D) of ABBV-151 administered as&#xD;
      monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety,&#xD;
      pharmacokinetics (PK), and preliminary efficacy of ABBV-151 alone and in combination with&#xD;
      budigalimab. The study will consist of 2 phases: dose escalation and dose expansion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">April 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 23, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation: Recommended Phase 2 Dose (RP2D) ABBV-151 Monotherapy</measure>
    <time_frame>Up to 28 days after the first dose of ABBV-151 monotherapy</time_frame>
    <description>The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for the dose expansion arms, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation portion of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Escalation: RP2D ABBV-151 + Budigalimab Combination Therapy</measure>
    <time_frame>Up to 28 days after the first dose of ABBV-151 and ABBV-181 combination therapy</time_frame>
    <description>The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for the dose expansion arms, based on safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamic (PD) data collected during the dose escalation portion of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion: Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 6 months after the first dose date of last participant in Dose Expansion</time_frame>
    <description>ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion: Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 6 months after the first dose date of last participant in Dose Expansion</time_frame>
    <description>The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion: Progression-free Survival (PFS)</measure>
    <time_frame>Up to approximately 6 months after the first dose date of last participant in Dose Expansion</time_frame>
    <description>Progression-free survival is defined as the time from the participant's first dose of study treatment (ABBV-151 or ABBV-181) to the first date of either disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of ABBV-151</measure>
    <time_frame>Up to approximately 70 days after initial dose of study drug</time_frame>
    <description>Maximum Serum Concentration (Cmax) of ABBV-151.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Serum Concentration (Tmax) of ABBV-151</measure>
    <time_frame>Up to approximately 70 days after initial dose of study drug</time_frame>
    <description>Time to maximum serum concentration (Tmax) of ABBV-151.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve over time from 0 to last measurable concentration (AUCτ) of ABBV-151</measure>
    <time_frame>Up to approximately 70 days after initial dose of study drug</time_frame>
    <description>Area under the serum concentration-time curve from time 0 to the time of the last measurable concentration (AUCτ) of ABBV-151.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal-phase Elimination Rate Constant (β) of ABBV-151</measure>
    <time_frame>Up to approximately 70 days after initial dose of study drug</time_frame>
    <description>Apparent terminal phase elimination rate constant (β or Beta) of ABBV-151.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Elimination Half-life (t1/2) of ABBV-151</measure>
    <time_frame>Up to approximately 70 days after initial dose of study drug</time_frame>
    <description>Terminal phase elimination half-life (t1/2) of ABBV-151.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of Budigalimab</measure>
    <time_frame>Up to approximately 70 days after initial dose of study drug</time_frame>
    <description>Maximum Serum Concentration (Cmax) of budigalimab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Serum Concentration (Tmax) of Budigalimab</measure>
    <time_frame>Up to approximately 70 days after initial dose of study drug</time_frame>
    <description>Time to maximum serum concentration (Tmax) of budigalimab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve over time from 0 to last measurable concentration (AUCτ) of Budigalimab</measure>
    <time_frame>Up to approximately 70 days after initial dose of study drug</time_frame>
    <description>Area under the serum concentration-time curve from time 0 to the time of the last measurable concentration (AUCτ) of budigalimab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal-phase Elimination Rate Constant (β) of Budigalimab</measure>
    <time_frame>Up to approximately 70 days after initial dose of study drug</time_frame>
    <description>Apparent terminal phase elimination rate constant (β or Beta) of budigalimab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Elimination Half-life (t1/2) of Budigalimab</measure>
    <time_frame>Up to approximately 70 days after initial dose of study drug</time_frame>
    <description>Terminal phase elimination half-life (t1/2) of budigalimab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 9 months after the first dose date of last participant</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vital Signs</measure>
    <time_frame>Up to approximately 6 months after the first dose date of last participant</time_frame>
    <description>Number of participants with clinically significant change from baseline in vital signs like systolic and diastolic blood pressure will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Laboratory Parameters</measure>
    <time_frame>Up to approximately 6 months after the first dose date of last participant</time_frame>
    <description>Number of participants with clinically significant change from baseline in clinical laboratory test results like hematology will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Electrocardiogram (ECG)</measure>
    <time_frame>Up to approximately 6 months after the first dose date of last participant</time_frame>
    <description>12-lead resting ECGs will be recorded. Parameters include RR interval, PR interval, QT interval, and QRS duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anti-drug Antibody (ADA)</measure>
    <time_frame>Up to approximately 6 months after the first dose date of last participant</time_frame>
    <description>The number of participants with anti-drug antibodies.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Advanced Solid Tumors Cancer</condition>
  <arm_group>
    <arm_group_label>ABBV-151 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Various doses of ABBV-151 administered during dose escalation, followed by dose expansion of ABBV-151 administered at the Recommended Phase 2 Dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-151 + Budigalimab Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Various doses of ABBV-151 plus budigalimab Dose A administered every 4 weeks (Q4W) during dose escalation, followed by dose expansion of ABBV-151 administered at the RP2D plus budigalimab Dose A administered Q4W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-151</intervention_name>
    <description>Liquid for intravenous infusion.</description>
    <arm_group_label>ABBV-151 + Budigalimab Combination Therapy</arm_group_label>
    <arm_group_label>ABBV-151 Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budigalimab</intervention_name>
    <description>Lyophilized powder for solution for intravenous infusion.</description>
    <arm_group_label>ABBV-151 + Budigalimab Combination Therapy</arm_group_label>
    <other_name>ABBV-181</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For Dose Escalation only: Participants with an advanced solid tumor who are considered&#xD;
             refractory to or intolerant of all existing therapy(ies) known to provide a clinical&#xD;
             benefit for their condition. Additionally, participants who have been offered standard&#xD;
             therapies and refused, or who are considered ineligible for standard therapies, may be&#xD;
             eligible for this study on a case-by-case basis, after discussion with and agreement&#xD;
             from the sponsor. Participants with triple-negative breast cancer (TNBC), pancreatic&#xD;
             adenocarcinoma, urothelial cancer, Hepatocellular carcinoma (HCC), or Head and neck&#xD;
             squamous cell carcinoma (HNSCC) who are being considered for the dose escalation&#xD;
             cohorts must also meet the histology specific eligibility criteria described below for&#xD;
             dose expansion&#xD;
&#xD;
          -  For Dose Expansion only participants must meet criteria specific to the type of&#xD;
             cancer:&#xD;
&#xD;
               -  TNBC - Female or male participants with confirmed breast adenocarcinoma that is&#xD;
                  ER-negative, PR-negative, and HER2-negative, (as defined per American Society of&#xD;
                  Clinical Oncology [ASCO]/College of American Pathology [CAP] guidelines), who&#xD;
                  must have disease progression during or after at least 1 systemic therapy that&#xD;
                  included a taxane in the metastatic or recurrent setting.&#xD;
&#xD;
               -  Pancreatic adenocarcinoma and have disease progression during or after 1 systemic&#xD;
                  therapy (gemcitabine monotherapy or in combination with other agents, FOLFIRINOX&#xD;
                  [or another regimen including both 5-fluorouracil and oxaliplatin], capecitabine&#xD;
                  monotherapy or in combination with other agents) administered in the adjuvant,&#xD;
                  locally advanced, or metastatic setting. If the therapy was used in an adjuvant&#xD;
                  setting, disease progression must have occurred within 6 months of completing&#xD;
                  adjuvant therapy.&#xD;
&#xD;
               -  Urothelial cancer of the bladder and urinary tract and must have progressed&#xD;
                  following treatment with a platinum-based regimen (administered in any line of&#xD;
                  therapy) and a programmed death 1/programmed death ligand 1 (PD1/PDL1) antagonist&#xD;
                  administered in the recurrent or metastatic setting (progression following a&#xD;
                  PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months&#xD;
                  of the last dose of anti-PD1 or anti-PDL1 therapy).&#xD;
&#xD;
               -  HCC and must have disease progression during or after 1 prior line of systemic&#xD;
                  therapy.&#xD;
&#xD;
               -  HNSCC (arising from the oral cavity, oropharynx, hypopharynx, or larynx) and must&#xD;
                  have progressed following treatment with platinum-based regimen (administered in&#xD;
                  any line of therapy) and a PD1/PDL1 antagonist administered in the recurrent or&#xD;
                  metastatic setting (progression following a PD1/PDL1 antagonist is defined as&#xD;
                  unequivocal progression on or within 3 months of the last dose of anti-PD1 or&#xD;
                  anti-PDL1 therapy).&#xD;
&#xD;
               -  CRC participants with microsatellite stable or mismatch repair proficient&#xD;
                  colorectal adenocarcinoma (as determined by PCR/NGS or IHC, respectively) who&#xD;
                  have received 1-2 prior chemotherapy regimens and who have refused or are&#xD;
                  ineligible for other approved therapies.&#xD;
&#xD;
          -  Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0&#xD;
             to 1.&#xD;
&#xD;
          -  Participant has adequate bone marrow, renal, hepatic, and coagulation function.&#xD;
&#xD;
          -  Must have a viral status consistent with the requirements described in the protocol&#xD;
             specific to type of cancer and stage of study (Dose Escalation or Dose Expansion).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For Dose Expansion only: Participants (except for participants with urothelial cancer&#xD;
             or HNSCC) who have had prior exposure to immunotherapies as listed in the protocol.&#xD;
&#xD;
          -  Has received anticancer therapy including chemotherapy, immunotherapy, radiation&#xD;
             therapy, biologic, herbal therapy, or any investigational therapy within a period of 5&#xD;
             half-lives or 28 days (whichever is shorter), prior to the first dose of the study&#xD;
             drug.&#xD;
&#xD;
          -  Participant has unresolved AEs &gt; Grade 1 from prior anticancer therapy except for&#xD;
             alopecia.&#xD;
&#xD;
          -  Has a history of primary immunodeficiency, bone marrow transplantation, solid organ&#xD;
             transplantation, or previous clinical diagnosis of tuberculosis.&#xD;
&#xD;
          -  Has a known uncontrolled metastases to the central nervous system (with certain&#xD;
             exceptions).&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 14 days prior to the first&#xD;
             dose of the study drug.&#xD;
&#xD;
          -  Has clinically significant uncontrolled condition(s).&#xD;
&#xD;
          -  History of inflammatory bowel disease, interstitial lung disease or pneumonitis,&#xD;
             myocarditis, Stevens-Johnson syndrome, toxic epidermal necrolysis or drug reaction&#xD;
             with eosinophilia and systemic symptoms (DRESS).&#xD;
&#xD;
          -  Live vaccine administration &lt;= 28 days prior to the first dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University /ID# 208356</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Celebration /ID# 224860</name>
      <address>
        <city>Celebration</city>
        <state>Florida</state>
        <zip>34747-4970</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Cancer Institute - Orlando /ID# 226953</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana Univ School Medicine /ID# 208384</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Michigan Med Ctr /ID# 221129</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center /ID# 209822</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-6402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute /ID# 208358</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University - The James /ID# 217611</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology /ID# 208930</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse /ID# 213236</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre /ID# 224961</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCL Saint-Luc /ID# 218466</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre /ID# 209423</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hopital Purpan /ID# 218667</name>
      <address>
        <city>TOULOUSE Cedex 9</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard /ID# 218515</name>
      <address>
        <city>Lyon CEDEX 08</city>
        <state>Rhone</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy /ID# 218668</name>
      <address>
        <city>Villejuif Cedex</city>
        <state>Val-de-Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin /ID# 218669</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center /ID# 209037</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel-Aviv</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center /ID# 222199</name>
      <address>
        <city>Tel Aviv-Yafo</city>
        <state>Tel-Aviv</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus /ID# 222198</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East /ID# 224808</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital /ID# 209421</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System Severance Hospital /ID# 218512</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital /ID# 218513</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pan American Center for Oncology Trials, LLC /ID# 217475</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona /ID# 221106</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz /ID# 220928</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia /ID# 221107</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital /ID# 218492</name>
      <address>
        <city>Taichung City</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital /ID# 218490</name>
      <address>
        <city>Taipei City</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors Cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>metastatic</keyword>
  <keyword>monotherapy</keyword>
  <keyword>combination therapy</keyword>
  <keyword>triple negative breast cancer (TNBC)</keyword>
  <keyword>pancreatic adenocarcinoma</keyword>
  <keyword>urothelial cancer</keyword>
  <keyword>hepatocellular carcinoma (HCC)</keyword>
  <keyword>head and neck squamous cell carcinoma (HNSCC)</keyword>
  <keyword>Colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

